Alternate Title
Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outline
Published Results
Trial Contact Information
Registry Information

Alternate Title

Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Previously Untreated Mantle Cell Lymphoma

Basic Trial Information

Phase	Type	Status	Age	Sponsor	Protocol IDs
Phase II	Treatment	Closed	18 and over	NCI	ECOG-E1499 E1499, NCT00070447

Objectives

1. Determine the time to treatment failure in patients with previously untreated mantle cell lymphoma treated with rituximab and CHOP chemotherapy comprising prednisone, cyclophosphamide, doxorubicin, and vincristine followed by yttrium Y 90 ibritumomab tiuxetan (IDEC-Y2B8; yttrium Y 90 Zevalin®).
2. Determine the response rate in patients at the completion of rituximab and CHOP and the incremental response rate after IDEC-Y2B8.
3. Determine the toxicity of this regimen in these patients.
4. Correlate serum rituximab levels with response in patients treated with this regimen.

Entry Criteria

Disease Characteristics:

• Histologically confirmed mantle cell lymphoma with expression of bcl-1 and CD20
  • Stage II-IV disease



• Measurable or evaluable disease
  • Measurable disease defined as at least 1 bidimensionally measurable lesion at least 2 cm by imaging scan
  • A spleen at least 17 cm or having discrete filling defects by CT scan will constitute evaluable disease provided that no explanation other than lymphomatous involvement (e.g., portal hypertension or other liver disease) is likely



• No known CNS lymphoma

Prior/Concurrent Therapy:

Biologic therapy

• No prior immunotherapy

Chemotherapy

• No prior chemotherapy

Endocrine therapy

• Prior corticosteroids allowed provided the course was no more than 2 weeks in duration

Radiotherapy

• No prior radiotherapy

Surgery

• Not specified

Patient Characteristics:

Age

• 18 and over

Performance status

• ECOG 0-2

Life expectancy

• At least 6 months

Hematopoietic

• WBC greater than 2,500/mm³*
• Platelet count greater than 100,000/mm³*

 [Note: *Unless due to disease in bone marrow]

Hepatic

• Bilirubin less than 1.5 mg/dL (1.5-3.0 mg/dL if due to liver involvement by lymphoma)
• ALT and AST no greater than 2.5 times upper limit of normal (unless due to liver involvement by lymphoma)

Renal

• Creatinine less than 2.0 mg/dL
• Calcium no greater than 11.5 mg/dL

Cardiovascular

• LVEF greater than 45%

Other

• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for 1 year after study participation
• HIV negative
• No other malignancy except treated carcinoma in situ of the cervix or squamous cell or basal cell skin cancer or any other surgically cured malignancy from which the patient has been disease-free for at least 3 years
• No other concurrent serious medical condition or active infection that would preclude ability to deliver standard prednisone, cyclophosphamide, doxorubicin, and vincristine (CHOP) chemotherapy

Expected Enrollment

A total of 57 patients will be accrued for this study within 2.8 years.

Outline

This is a multicenter study.

• CHOP chemotherapy and rituximab: Patients receive cyclophosphamide IV, doxorubicin IV, vincristine IV, and rituximab IV on day 1 and oral prednisone on days 1-5 (R + CHOP). Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.

  Patients who have responding or stable disease proceed to radioimmunotherapy.




• Radioimmunotherapy: Within 4-7 weeks after the completion of R + CHOP chemotherapy, patients receive rituximab IV and an imaging dose of indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1. Patients then undergo whole body gamma imaging scans during the first day (2-24 hours) and the second or third day (48-72 hours) after injection. In the absence of altered biodistribution, patients receive rituximab IV followed by yttrium Y 90 ibritumomab tiuxetan (IDEC-Y2B8; yttrium Y 90 Zevalin®) IV over 10 minutes on day 8.

Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually for 5 years.

Smith MR, Zhang L, Gordon LI, et al.: Phase II study of R-CHOP followed by 90Y-ibritumomab tiuxetan in untreated mantle cell lymphoma: Eastern Cooperative Oncology Group study E1499. [Abstract] Blood 110 (11): A-389, 2007.

Smith MR, Chen H, Gordon L, et al.: Phase II study of rituximab + CHOP followed by 90Y-ibritumomab tiuxetan in patients with previously untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group Study (E1499). [Abstract] J Clin Oncol 24 (Suppl 18): A-7503, 422s, 2006.

Trial Contact Information

Trial Lead Organizations

Eastern Cooperative Oncology Group

Mitchell Smith, MD, PhD, Protocol chair		Ph: 215-728-2674; 888-369-2427 Email: m_smith@fccc.edu
Leo Gordon, MD, Protocol co-chair		Ph: 312-695-4546 Email: l-gordon@northwestern.edu

Registry Information
Official Title		Phase II Study of Rituximab (NSC 687451) + CHOP Followed by 90Y-Ibritumomab Tiuxetan (NSC 710085) in Patients with Previously Untreated Mantle Cell Lymphoma
Trial Start Date		2003-11-14
Registered in ClinicalTrials.gov		NCT00070447
Date Submitted to PDQ		2003-08-27
Information Last Verified		2004-10-26
NCI Grant/Contract Number		U10-CA21115

Back to Top